BiondVax Pharmaceuticals Debt 2024

BiondVax Pharmaceuticals Aktienanalyse

What does BiondVax Pharmaceuticals do?

BiondVax Pharmaceuticals Ltd is an Israeli biopharmaceutical company specializing in the development and production of vaccines. The company was founded in 2003 and has since developed an innovative approach to preparing influenza vaccines. BiondVax's business model is focused on meeting the growing demand for vaccines while ensuring better efficacy and safety. The company uses the latest technologies and research methods to carefully examine the properties of viruses and develop tailor-made vaccines based on that information. BiondVax offers a wide range of products that focus on protecting against influenza viruses. The company's most important product is the M-001 vaccine, which has broad efficacy against various types of influenza viruses. This vaccine differs from conventional vaccines by independently stimulating and enhancing immunity, resulting in longer-lasting protection. The company is also developing other vaccines aimed at protecting against other infectious diseases such as herpes simplex or AIDS. A unique feature of BiondVax is the use of a targeted approach to cancer treatment, where the patient's immune system is specifically activated to kill cancer cells. BiondVax is a dynamic company that continuously invests in improving its technology and products. Since its founding, the company has made significant progress and achieved a number of milestones. For example, in 2017, the company received an important approval from the US Food and Drug Administration, allowing it to conduct a clinical trial process for its vaccine. BiondVax has also formed partnerships with other leading companies in the healthcare industry to support its research and development. Collaborating with companies such as Merck, Novartis, or the US Department of Defense allows BiondVax to further expand its business and develop more effective vaccines. Over the years, BiondVax has introduced numerous innovations in the industry. For example, the company has specialized in designing peptides, which are proteins that can serve as the basis for vaccines. The company has also utilized the latest technologies in immunology to make its vaccines even safer and more effective. Overall, BiondVax Pharmaceuticals Ltd has made impressive progress in recent years and has established itself as a leading company in the field of vaccine development. Through its innovative technologies and targeted approach to disease prevention, BiondVax is able to significantly impact the healthcare industry and serve a wider range of patients than before. BiondVax Pharmaceuticals ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Debt Details

Understanding BiondVax Pharmaceuticals's Debt Structure

BiondVax Pharmaceuticals's total debt refers to the cumulative financial obligations the company owes to external parties. This can include short-term and long-term borrowings, bonds, loans, and other financial instruments. Assessing the company's debt levels is crucial for evaluating its financial health, risk profile, and ability to fund operations and expansions.

Year-to-Year Comparison

Analyzing BiondVax Pharmaceuticals's debt structure over the years provides insights into the firm’s financial strategy and stability. A reduction in debt can indicate financial strength and operational efficiency, while an increase may signal growth investments or potential financial challenges ahead.

Impact on Investments

Investors pay close attention to BiondVax Pharmaceuticals’s debt levels as they can influence the company’s risk and return profiles. Excessive debt can lead to financial strain, while moderate and well-managed debt can be a catalyst for growth and expansion, making it a critical aspect of investment evaluations.

Interpreting Debt Fluctuations

Shifts in BiondVax Pharmaceuticals’s debt levels can be attributed to various operational and strategic factors. An increase in debt might be geared towards funding expansion projects or enhancing operational capacity, while a decrease may indicate profit realizations or an approach to minimize financial risk and leverage.

Frequently Asked Questions about BiondVax Pharmaceuticals stock

What is the debt of BiondVax Pharmaceuticals this year?

BiondVax Pharmaceuticals has a debt level of 3.9 ILS this year.

What was the debt of BiondVax Pharmaceuticals compared to the previous year?

The debt of BiondVax Pharmaceuticals has increased by 0% compared to the previous year dropped.

What are the consequences of high debt for investors in BiondVax Pharmaceuticals?

High debt can pose a risk for investors of BiondVax Pharmaceuticals, as it can weaken the company's financial position and hinder its ability to fulfill its obligations.

What are the consequences of low debt for investors of BiondVax Pharmaceuticals?

Low debt means that BiondVax Pharmaceuticals has a strong financial position and is able to fulfill its obligations without overburdening its finances.

How does an increase in debt from BiondVax Pharmaceuticals affect the company?

An increase in debt of BiondVax Pharmaceuticals can adversely affect the financial condition of the company and result in a higher burden on its finances.

How does a reduction of debt of BiondVax Pharmaceuticals affect the company?

A reduction in debt of BiondVax Pharmaceuticals can strengthen the company's financial position and improve its ability to meet its financial obligations.

What are some factors that influence the debt of BiondVax Pharmaceuticals?

Some factors that can influence the debt of BiondVax Pharmaceuticals include investments, acquisitions, operating costs, and revenue development.

Why are the debts of BiondVax Pharmaceuticals so important for investors?

The debts of BiondVax Pharmaceuticals are important for investors as they serve as an indicator of the company's financial stability. It provides investors with information on how the company fulfills its financial obligations.

What strategic measures can BiondVax Pharmaceuticals take to change the debt?

To change the debt, BiondVax Pharmaceuticals can take measures such as cost savings, increasing revenue, selling assets, making investments, or forming partnerships. It is important for the company to conduct a thorough review of its financial situation to determine the best strategic actions to change its debt.

How much dividend does BiondVax Pharmaceuticals pay?

Over the past 12 months, BiondVax Pharmaceuticals paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, BiondVax Pharmaceuticals is expected to pay a dividend of 0 ILS.

What is the dividend yield of BiondVax Pharmaceuticals?

The current dividend yield of BiondVax Pharmaceuticals is .

When does BiondVax Pharmaceuticals pay dividends?

BiondVax Pharmaceuticals pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of BiondVax Pharmaceuticals?

BiondVax Pharmaceuticals paid dividends every year for the past 0 years.

What is the dividend of BiondVax Pharmaceuticals?

For the upcoming 12 months, dividends amounting to 0 ILS are expected. This corresponds to a dividend yield of 0 %.

In which sector is BiondVax Pharmaceuticals located?

BiondVax Pharmaceuticals is assigned to the 'Health' sector.

Wann musste ich die Aktien von BiondVax Pharmaceuticals kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of BiondVax Pharmaceuticals from 11/19/2024 amounting to 0 ILS, you needed to have the stock in your portfolio before the ex-date on 11/19/2024.

When did BiondVax Pharmaceuticals pay the last dividend?

The last dividend was paid out on 11/19/2024.

What was the dividend of BiondVax Pharmaceuticals in the year 2023?

In the year 2023, BiondVax Pharmaceuticals distributed 0 ILS as dividends.

In which currency does BiondVax Pharmaceuticals pay out the dividend?

The dividends of BiondVax Pharmaceuticals are distributed in ILS.